Catalyst Wire Dossier Catalyst Wire Dossier

Tucatinib

tucatinib · Seagen (Seattle Genetics) and Astellas Pharma
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Tucatinib, covering 2020-09-28 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive [Phase 2, Phase 3]

See pricing